Private Equity Firms Invest in PCI Pharma at $10 Billion Valuation

PCI Pharma Services, a global contract development and manufacturing organization specializing in innovative biotherapies, has secured a strategic investment led by Bain Capital alongside existing investor Kohlberg & Company and supported by Mubadala and Partners Group. This funding, reportedly valuing PCI at around $10 billion, aims to accelerate the company's growth through expanding its services, geographic footprint, and manufacturing capacities, particularly in sterile fill-finish and specialized drug production. PCI's management, led by CEO Salim Haffar, plans to leverage this investment to enhance its commercial, clinical trial services, and manufacturing businesses, prioritizing U.S. pharmaceutical manufacturing infrastructure. Partners Group has exited a portion of its investment but reinvested significantly to support PCI's future growth. The company, with nearly 8,000 employees and 30 global sites, has been involved in numerous product launches, including notable drugs like Novo Nordisk's Wegovy. This funding round continues PCI's evolution under private equity ownership, aiming to meet increasing biopharmaceutical demands worldwide.